Non-invasive imaging biomarker

Non-invasive imaging biomarker Reducing biopsies and improving dystrophin analysis Biopsies have become a difficult necessity for Duchenne patients who are involved in clinical trials. In addition to the stress on patients, each muscle can present disease differently,...

LTBP4

LTBP4 Targeting muscle inflammation and fibrosis With the funds raised in 2016, the DRF is tackling inflammation and fibrosis, which are two key problems for Duchenne boys. It is believed that the protein LTBP4 prevents the activation of a key biological pathway...

Solid Biosciences’ gene therapy

Solid GT Ground-breaking gene therapy platform for Duchenne (IGNITE DMD Clinical Trial) In May 2026, Solid Biosciences announced that the first participant had been dosed in the Phase III clinical study of its next-generation gene therapy, SGT-003. The patient was...

Vamorolone

Vamorolone Alternative to existing steroids for all with Duchenne In January 2024, vamrolone became the first drug for all people with Duchenne muscular dystrophy to be approved in the US, the EU and the UK. In December 2024, it was approved by NICE for use on the...